The Brighterside of News on MSN1h
Revolutionary new cancer treatment destroys tumors in less than 6 days
Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...
Trump Didn't 'Cancel Cancer Research' — But His Directives Paused NIH Meetings To Dole Out Funds
Meetings designed to distribute grant money to fund research were canceled as part of a communications freeze at health ...
“Pushing the Boundaries of Radiation Treatment”: Breakthrough Cancer Therapy Advances to Clinical Trials
A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...
EurekAlert!11d
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.
Pharm Exec2d
Merck Launches Phase III Trial Evaluating Zilovertamab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
As federal research money comes under scrutiny, here's what it funds in Houston
Houston’s medical powerhouses are among those waiting to see how federal changes will shake out, and for good reason — some ...
News Medical on MSN13d
Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
appliedclinicaltrialsonline11d
Pfizer Shares Positive Data from Phase III BREAKWATER Trial of Braftovi Combination Following Accelerated Approval
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...